> Details

Hauschild, Axel; Weichenthal, Michael; Rass, Knuth; Linse, Ruthild; Berking, Carola; Böttjer, Jörg; Vogt, Thomas; Spieth, Konstanze; Eigentler, Thomas; Brockmeyer, Norbert H.; Stein, Annette; Näher, Helmut; Schadendorf, Dirk; Mohr, Peter; Kaatz, Martin; Tronnier, Michael; Hein, Rüdiger; Schuler, Gerold; Egberts, Friederike; Garbe, Claus

Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial
  • Contributor: Hauschild, Axel; Weichenthal, Michael; Rass, Knuth; Linse, Ruthild; Berking, Carola; Böttjer, Jörg; Vogt, Thomas; Spieth, Konstanze; Eigentler, Thomas; Brockmeyer, Norbert H.; Stein, Annette; Näher, Helmut; Schadendorf, Dirk; Mohr, Peter; Kaatz, Martin; Tronnier, Michael; Hein, Rüdiger; Schuler, Gerold; Egberts, Friederike; Garbe, Claus
  • imprint: American Society of Clinical Oncology (ASCO), 2010
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2009.23.1704
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Purpose</jats:title><jats:p> Low-dose (LD) interferon (IFN) alfa (LDI) has demonstrated a consistent disease-free survival benefit for patients with clinically lymph node–negative melanoma in clinical trials. However, the optimal duration of treatment is still under discussion, and no previous trial has evaluated this question specifically. A prolongation of LDI from 18 months to 60 months might be of clinical benefit for patients with intermediate or high-risk melanoma. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Eight hundred fifty patients with resected cutaneous melanoma of at least 1.5 mm tumor thickness were included in this prospective randomized, multicenter trial in Germany and Austria. Patients had to be clinically lymph node–negative, and sentinel node biopsy (SLNB) was performed in a majority of cases. They were randomly assigned to receive 3 MU IFNα2a three times a week subcutaneously for either 18 months (arm A) or 60 months (arm B). </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Of 850 randomly assigned patients, 840 were eligible for evaluation after a median follow-up of 4.3 years. Tumor thickness and other relevant prognostic factors were well balanced between both groups. SLNB was performed in 635 patients (75.6%), with a positivity rate of 18.0% in arm A and 17.5% in arm B. Neither relapse-free survival (arm A, 75.6% v arm B, 72.6%; P = .72; hazard ratio, 1.05; 95% CI, 0.80 to 1.39) nor distant-metastasis–free survival (81.9% v 79.7%; P = .56; HR, 1.10; 95% CI, 0.80 to 1.52) or overall survival (85.9% v 84.9%; P = .86; HR, 1.03; 95% CI, 0.71 to 1.50) showed significant differences. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> A prolongation of conventional LDI therapy from 18 to 60 months showed no clinical benefit in patients with intermediate and high-risk primary melanoma. </jats:p></jats:sec>
  • Access State: Open Access